tetano
Editor, Senior Moderator
J Infect Dis
. 2025 Oct 17;232(Supplement_3):S327-S332.
doi: 10.1093/infdis/jiaf152. Improving Access to Influenza Testing and Treatment: Is It Time for Over-the-counter Oseltamivir?
Kyueun Lee[SUP] 1 [/SUP], Andrew T Pavia[SUP] 2 [/SUP], Janet A Englund[SUP] 3 4 [/SUP]
Affiliations
Oseltamivir, an antiviral medication that has been used for influenza prophylaxis and treatment since 1999 and now available as a generic drug, is being considered for over-the-counter (OTC) status to allow individuals to access treatment without a prescription. This proposal has engendered controversy. With the rising availability of at-home diagnostic tests and the ever-present threat of an influenza pandemic, it is timely to revisit issues surrounding this controversy. In this commentary, we examine the potential benefits and risks of reclassifying oseltamivir as an OTC drug to enhance access to rapid influenza treatment. Additionally, we explore alternative models to improve oseltamivir accessibility, potentially utilizing rapid influenza testing. As newer drugs to treat influenza are proven safe and effective, they would be subject to similar considerations.
Keywords: antivirals; influenza; oseltamivir; rapid viral testing; respiratory viruses.
. 2025 Oct 17;232(Supplement_3):S327-S332.
doi: 10.1093/infdis/jiaf152. Improving Access to Influenza Testing and Treatment: Is It Time for Over-the-counter Oseltamivir?
Kyueun Lee[SUP] 1 [/SUP], Andrew T Pavia[SUP] 2 [/SUP], Janet A Englund[SUP] 3 4 [/SUP]
Affiliations
- PMID: 41102605
- DOI: 10.1093/infdis/jiaf152
Oseltamivir, an antiviral medication that has been used for influenza prophylaxis and treatment since 1999 and now available as a generic drug, is being considered for over-the-counter (OTC) status to allow individuals to access treatment without a prescription. This proposal has engendered controversy. With the rising availability of at-home diagnostic tests and the ever-present threat of an influenza pandemic, it is timely to revisit issues surrounding this controversy. In this commentary, we examine the potential benefits and risks of reclassifying oseltamivir as an OTC drug to enhance access to rapid influenza treatment. Additionally, we explore alternative models to improve oseltamivir accessibility, potentially utilizing rapid influenza testing. As newer drugs to treat influenza are proven safe and effective, they would be subject to similar considerations.
Keywords: antivirals; influenza; oseltamivir; rapid viral testing; respiratory viruses.